The corporate team at Penningtons Manches Cooper has acted for Oxford-based Caristo Diagnostics in a multimillion-pound investment round. The round was led by BGF and existing investors including Oxford Sciences Innovation (OSI), Longwall Ventures and the Oxford Technology & Innovation Fund (OTIF).
Caristo is committed to transforming health outcomes through clinical and scientific innovation. The funding will be used to roll-out Caristo’s CaRi-Heart®, a first-of-its-kind technology that has the power to detect ‘invisible’ risk in people with possible heart disease by using routine heart scans. CaRi-Heart® recently received its CE mark accreditation, meaning it can be rolled out across the UK and Europe.
Penningtons Manches Cooper has acted for Caristo since its spin-out from the University of Oxford in 2018. The team was led by partner James Went and senior associate Attilio Leccisotti.